Clinical implications of tumor necrosis factor receptor 2 in breast cancer

  • Authors:
    • Fuqian Yang
    • Zhonghua Zhao
    • Nana Zhao
  • View Affiliations

  • Published online on: June 19, 2017     https://doi.org/10.3892/ol.2017.6410
  • Pages: 2393-2398
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tumor necrosis factor receptor 2 (TNFR2) is a member of the tumor necrosis factor receptor family. Its high expression and oncogenic roles have been reported in several types of tumors in previous years. However, the clinical implication of TNFR2 in breast cancer (BC) tissue (i.e., not soluble TNFR2 in blood or genetic variation of TNFR2) has not been reported. In the present study, TNFR2 expression was detected in BC tissue using immunohistochemistry and, to the best of our knowledge, it was confirmed for the first time that TNFR2 was positively associated with increased tumor size, advanced clinical stage and higher pathological grade. Survival analysis revealed that TNFR2 was positively associated with shorter overall survival (OS) time and disease‑free survival (DFS) time. In addition, univariate regression analysis demonstrated that TNFR2 expression (P=0.045), tumor size (P<0.0001), clinical stage (P<0.0001), pathological grade (P=0.002), estrogen and progesterone receptor and human epidermal growth factor receptor 2 (HER2) triple‑status (P=0.001) all had a significant impact on the OS rate of patients with BC. TNFR2 expression (P=0.017), age (P=0.011), menopausal status (P<0.0001), tumor size (P=0.016), clinical stage (P=0.005), pathological grade (P=0.002) and estrogen/progesterone receptor and HER2 triple‑status (P=0.008) were all shown to significantly impact the DFS rate of patients with BC. Multivariate regression analysis showed that only clinical stage (P=0.024), estrogen and progesterone receptor status and HER2 status (P=0.009) had a significant impact on the OS rate of patients with BC, while TNFR2 expression (P=0.043) and menopausal status (P=0.033) were shown to significantly impact the DFS rate of patients with BC. These data indicated that TNFR2 may perform important roles in the progression and prognosis of BC. This enriches previous understanding about TNFR2 in BC.
View Figures
View References

Related Articles

Journal Cover

August-2017
Volume 14 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang F, Zhao Z and Zhao N: Clinical implications of tumor necrosis factor receptor 2 in breast cancer. Oncol Lett 14: 2393-2398, 2017
APA
Yang, F., Zhao, Z., & Zhao, N. (2017). Clinical implications of tumor necrosis factor receptor 2 in breast cancer. Oncology Letters, 14, 2393-2398. https://doi.org/10.3892/ol.2017.6410
MLA
Yang, F., Zhao, Z., Zhao, N."Clinical implications of tumor necrosis factor receptor 2 in breast cancer". Oncology Letters 14.2 (2017): 2393-2398.
Chicago
Yang, F., Zhao, Z., Zhao, N."Clinical implications of tumor necrosis factor receptor 2 in breast cancer". Oncology Letters 14, no. 2 (2017): 2393-2398. https://doi.org/10.3892/ol.2017.6410